Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-07-28 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
股东会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for Shareholders' Meetings" of a company, detailing the governance, procedures, rights, and responsibilities related to shareholders' meetings. It extensively covers the rules for convening, proposing, notifying, conducting, and voting in shareholders' meetings. There is no financial data, earnings information, or audit results presented. The content is focused on governance and procedural rules for shareholder meetings rather than reporting financial performance or announcing results. Therefore, this document fits best under Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-07-28 Chinese
独立董事专门会议工作制度
Governance Information Classification · 95% confidence The document is titled as a working system for the Independent Directors' Special Meeting of 科兴生物制药股份有限公司. It outlines governance procedures, duties, meeting protocols, and responsibilities of independent directors. It references laws and regulations related to corporate governance and independent directors but does not contain financial data, audit results, or financial performance information. It is a governance-related internal rules document rather than a report, announcement, or financial filing. Therefore, it fits best under Governance Information (CGR). The document length is 2172 characters, which is relatively short but contains substantive governance content, not just an announcement or notice.
2025-07-28 Chinese
会计师事务所选聘制度
Governance Information Classification · 95% confidence The document is a detailed internal policy document titled '会计师事务所选聘制度' (Accounting Firm Selection System) issued by the board of directors of 科兴生物制药股份有限公司. It outlines procedures, requirements, and governance related to the selection, appointment, and replacement of the company's external auditors (accounting firms). It includes references to regulatory compliance, internal controls, evaluation criteria, and disciplinary measures related to audit firms. There are no financial statements, audit reports, or direct financial results presented. The document is not an audit report itself, nor an annual or interim report. It is a governance-related document detailing internal rules and procedures concerning auditor selection and oversight. Therefore, it fits best under Governance Information (CGR). The document length is about 4800 characters, which is substantive and not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2025-07-28 Chinese
独立董事提名人声明与承诺（方俊辉）
Board/Management Information Classification · 100% confidence The document is a formal statement and commitment regarding the nomination of an independent director candidate for the board of a company. It details the qualifications, legal compliance, independence criteria, and absence of adverse records for the nominee. There is no financial data, no report of financial results, no voting results, no announcement of a report publication, and no mention of any other regulatory filings or legal proceedings. The content is focused on board/management information, specifically the nomination of a board member. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is short and it is a declaration rather than a report or announcement of a report, so it is not RPA or RNS.
2025-07-28 Chinese
董事及高级管理人员离职管理制度
Governance Information Classification · 95% confidence The document is titled '董事及高级管理人员离职管理制度' which translates to 'Management System for the Resignation of Directors and Senior Management' of 科兴生物制药股份有限公司 (a pharmaceutical company). The content details rules and procedures related to the resignation, obligations, and responsibilities of directors and senior management personnel, including legal compliance and company governance references. It is a governance-related internal policy document rather than a financial report, announcement, or regulatory filing. It does not contain financial data, earnings, voting results, or capital changes. It is not a report publication announcement or certification. Therefore, the document fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3580 characters, which is consistent with a detailed governance policy document. Confidence is high due to clear governance content and absence of financial or regulatory filing elements.
2025-07-28 Chinese
子公司管理制度
Governance Information Classification · 95% confidence The document is titled as a subsidiary management system of a pharmaceutical company, detailing internal governance, management, financial control, investment, reporting, audit supervision, and disciplinary measures for subsidiaries. It is a comprehensive internal governance and management policy document rather than a financial report, earnings release, or regulatory filing. It does not contain financial statements, audit opinions, or shareholder meeting materials. It is not an announcement or a presentation but a detailed governance and management system document. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-07-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.